Trial Profile
Does CMV Reactivation Cause Functional Impairment of CMV Specific CD4+ T-cells? The Potential for Valaciclovir to Prevent CMV-mediated Adverse Modulation of the Immune System in Patients With ANCA-associated Vasculitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Valaciclovir (Primary)
- Indications Cytomegalovirus infections; Granulomatosis with polyangiitis
- Focus Proof of concept; Therapeutic Use
- Acronyms CANVAS
- 20 Aug 2018 New trial record
- 09 Aug 2018 Results published in the Journal of Infectious Diseases